Huntington’s disease (HD): treatment

Treatments of chorea: VMAT blockers

• Tetrabenazine
• Deutetrabenazine
• Valbenazine

Treatments of chorea: Neuroleptics

Treatments of chorea: other agents

Treatments of depression

Treatments of altered sleep-wake cycle

Mood stabilisers

Physical exercise

Investigational treatments

Acronym

References

1. Armstrong MJ, Miyasaki JN. Evidence-based guideline: pharmacologic treatment of chorea in Huntington disease. Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 2012; 79:597–603.
2. Novak MJU, Sarah J Tabrizi SJ. Huntington’s disease. BMJ 2010; 340:c3109.
3. Huntington Study Group, Frank S, Testa CM, Stamler D, et al. Effect of deutetrabenazine on chorea among patients with Huntington disease. JAMA 2016; 316:40-50. 
4. Frank S, Stamler D, Kayson E, et al; Huntington Study Group/Alternatives for Reducing Chorea in Huntington Disease Investigators. Safety of converting from tetrabenazine to deutetrabenazine for the treatment of chorea. JAMA Neurol 2017; doi: 10.1001/jamaneurol.2017.1352 (Epub ahead of print).
5. Dean M, Sung VW. Review of deutetrabenazine: a novel treatment for chorea associated with Huntington's disease. Drug Des Devel Ther 2018; 12:313-319. 
6. And 9 more. Subscribe to see the full list

Related checklists

• Huntington’s disease (HD): pre-manifest features
• Huntington’s disease (HD): genetics and variants
• Huntington’s disease (HD): clinical features
• Huntington’s disease HD: differential diagnosis
• Juvenile Huntington’s disease (JHD)